NgoMeyi 2022, uShenzhen Jment Technology Co, Ltd (lapha abizwa ngokuthi yi-jymed peptide) ethunyelwe isicelo sobhaliso lweSemaglutide API kwi-US Food and Drug Administration (FMA) (Inombolo yokubhalisa ye-DMF: idlulile Ukubuyekezwa kobuqotho, kanye nesimo samanje "a". I-ymed peptide ibe ngomunye wabakhiqizi bokuqala abakhiqizi be-semaglutide API eChina ukudlulisa isibuyekezo se-US FDA.

NgoFebhuwari 16, 2023, iwebhusayithi esemthethweni yeSikhungo Sokuhlola Izidakamizwa samenyezelwa ukuthi iSemaglutide API [Inombolo Yokubhalisa: Inombolo yokubhalisa: I-HUBEI JXBIO Co, Ltd. yamukelwe. I-Peptide yeJymed isiphenduke ngomunye wabakhiqizi bezidakamizwa ezibonakalayo ezingavuthiwe ezibonakalayo zesicelo sakho sokuthengisa salo mkhiqizo samukelwe eChina.

Mayelana Semaglutide
ISemaglutide yi-agonist ye-glp-1 receptor ethuthukiswe nguNovo Nordisk (Novo Nordisk). Umuthi ungakhulisa imetabolism kashukela ngokuvuselela amaseli we-pancreatic β ukufihla i-insulin, futhi uvimbele imfihlo ye-glucain kusuka kuma-pancreatic α cell ukunciphisa ukudla nokudla kwegazi okulula. Ngaphezu kwalokho, kunciphisa ukudla ngokudla ngokunciphisa isifiso sokudla kanye nokunciphisa ukugaya esiswini, okugcina kunciphisa amafutha omzimba nengculazi ekunciphiseni isisindo.
1. Imininingwane eyisisekelo
Ngokombono wesakhiwo, uma kuqhathaniswa neLiraglutide, ushintsho olukhulu lwe-semaglutide ukuthi ama-aeas amabili angezwe ohlangothini lwe-lysine, kanye ne-palmitic acid kuthathelwe indawo yi-octadecanedioic acid. U-Alanine wathathelwa indawo yi-AIB, eyandisa kakhulu ihafu-impilo yeSemaglutide.

Ukwakheka kwesibalo se-semaglutide

2. Izinkomba
1) Semaglutide anganciphisa ingozi yemicimbi yenhliziyo ezigulini ezine-T2D.
2) Semaglutide wehlisa ushukela wegazi ngokuvuselela imfihlo ye-insulin kanye nokunciphisa imfihlo ye-glucagon. Lapho ushukela wegazi uphakeme, ukufunwa kwe-insulin kuyavuswa futhi imfihlo ye-glucagon ivinjelwe.
3) I-Nordo Nordisk Pill Clinical Climicy ikhombisile ukuthi ukuphathwa ngomlomo kwe-semaglutide 1mg, 0.5mg kunemiphumela engcono ye-hypoglycemic kanye nemiphumela yokuncipha kwesisindo kune-trulcity (i-dulaglutide) 1.5mg, 0.75mg.
3) I-Oral Semaglutide iyikhadi le-Trump leNovo Nordisk. Ukuphathwa ngomlomo kanye ngosuku kungaqeda ukuphazamiseka nokuhlushwa kwengqondo okubangelwa umjovo, futhi kungcono kune-liraglutide (umjovo kanye ngesonto). Imiphumela ye-hypoglycemimic kanye nemiphumela yokulahleka kwezidakamizwa ezijwayelekile njenge, emplagliflozin (Sglt-2) ne-Sitiptipin (DPP-4) zikhanga kakhulu iziguli nodokotela. Uma kuqhathaniswa nokwakhiwa komjovo, ukwakheka komlomo kuzothuthukisa kakhulu usizo lokusetshenziswa komtholampilo kweSemaglutide.

3. Isifinyezo
Cishe ngenxa yokusebenza kwayo okuhle kakhulu ku-hypoglycemimic, ukunciphisa umzimba, ukuphepha nezinzuzo zenhliziyo ama-semaglutide abe yi-semaglutide esesiphuthumayo - izinga le-New Star "elinethemba elikhulu lemakethe.